Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ744MR)

This product GTTS-WQ744MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ744MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3657MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12661MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ4077MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ12227MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ1612MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ10098MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ3142MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ6618MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW